Entera Bio (NASDAQ:ENTX) Shares Up 6.9% - Here's What Happened

Key Points

• Entera Bio shares rose 6.9% to $2.875, with trading volume at 397,909 shares—61% below the average session volume.
• Analyst sentiment is mixed but leans positive: the stock has a consensus “Moderate Buy” rating and a $9.60 price target, compared with its roughly $2.88 trading price. Guggenheim and Lifesci Capital set targets of $11 and $10, respectively, while some ratings remained negative.
• The company reported a quarterly loss of $0.14 per share, missing the $0.08 consensus estimate. Entera Bio is developing oral versions of injectable protein and peptide therapies, including candidates for osteoporosis and hypoparathyroidism.

Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) traded up 6.9% on Wednesday. The company traded as high as $2.86 and last traded at $2.8750. 397,909 shares changed hands during trading, a decline of 61% from the average session volume of 1,022,903 shares. The stock had previously closed at $2.69.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a report on Friday, July 17th. Wall Street Zen upgraded shares of Entera Bio to a "sell" rating in a research note on Saturday, August 8th. Guggenheim initiated coverage on shares of Entera Bio in a research report on Thursday, September 24th. They set a "buy" rating and a $11.00 price target on the stock. HC Wainwright restated a "buy" rating on shares of Entera Bio in a research note on Wednesday, June 24th. Finally, Lifesci Capital began coverage on Entera Bio in a report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $9.60.

Entera Bio Stock Up 9.3%

The stock has a 50 day simple moving average of $2.93 and a 200 day simple moving average of $1.89. The company has a market capitalization of $511.16 million, a price-to-earnings ratio of -8.27 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). As a group, analysts forecast that Entera Bio Ltd. will post -0.4 EPS for the current year.

Institutional Trading of Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Renaissance Technologies LLC boosted its position in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 338.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 473,442 shares of the company's stock after purchasing an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company's proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio's lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.